



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

**Oversight Committee Meeting Minutes
September 14, 2022**

NOTE: Unless the information is confidential, the reports, presentations, and grant award information referenced in the minutes are available at <http://ocmeetings.cprit.texas.gov> in the “Oversight Committee Board Packet” section for the corresponding meeting date.

Call to Order – Agenda Item 1

Presiding Officer Dr. Bill Rice announced a quorum present and called the meeting to order at 9:00 a.m.

Roll Call/Excused Absences – Agenda Item 2

Committee Members Present

Mahendra Patel, M.D., P.A. (via videoconference pursuant to Tex. Gov’t Code § 551.127)
David Cummings, M.D. (via videoconference pursuant to Tex. Gov’t Code § 551.127)
Donald (Dee) Margo (via videoconference pursuant to Tex. Gov’t Code § 551.127)
Ambrosio Hernandez, M.D. (via videoconference pursuant to Tex. Gov’t Code § 551.127)
Will Montgomery (via videoconference pursuant to Tex. Gov’t Code § 551.127)
Cindy Barberio Payne (via videoconference pursuant to Tex. Gov’t Code § 551.127)
Bill Rice, M.D.
Craig Rosenfeld, M.D. (via videoconference pursuant to Tex. Gov’t Code § 551.127)

Presiding Officer Dr. Rice noted for the record that Oversight Committee members are attending the meeting via videoconference, as permitted by the Texas Open Meetings Act. He also noted that he is presiding over the meeting in accordance with Oversight Committee bylaws, which permit another member of the Oversight Committee to preside over the meeting when the Presiding Officer is not able to physically attend the open meeting.

Public Comment – Agenda Item 3

Presiding Officer Dr. Rice noted for the record that no member of the public requested to provide comments.

Chief Executive Officer Report – Agenda Item 4

Presiding Officer Dr. Rice recognized Chief Executive Officer Wayne Roberts to present his report. Mr. Roberts informed members CPRIT has sufficient funds available to support all grant awards proposed for approval today.

Chief Compliance Officer Report and Compliance Certification for the Proposed Grant Awards – Agenda Item 5

Presiding Officer Dr. Rice recognized Chief Compliance Officer Vince Burgess to present the Compliance Report and Compliance Certification of Grant Award Process.

Mr. Burgess presented the Compliance Certification for the proposed Academic Research and Product Development Research grant awards, confirming that the proposed awards and review process complied with all applicable state and agency requirements.

Chief Scientific Officer Report and Grant Award Recommendations – Agenda Item 6

Presiding Officer Dr. Rice recognized Dr. Le Beau to present the academic research program award recommendations.

Dr. Le Beau directed Oversight Committee members to Table 1 on page 6 of the Proposed Grant Awards Book which displayed the Scientific Review Council (SRC) and Program Integration Committee (PIC) recommendations for the FY 2022 review cycle 2 and recruitment cycle 22.10, which included 25 awards totaling \$36,768,514. She explained that due to limited funds available in FY 2022, the SRC waited to recommend these awards until the start of FY 2023.

Dr. Le Beau provided an overview of the recommended awards.

ID	RFA	Score	Application Title	PI	PI Organization	Budget
RP220582	CFSA	1.0	Establish New Cryo-EM Core Services to Drive Cancer Research and Drug Discovery at UT Southwestern Medical Center	Rosen, Michael	The University of Texas Southwestern Medical Center	\$4,000,000
RP220646	CFSA	1.8	Patient-Derived Xenograft and Advanced In Vivo Models (PDX-AIM) Core Facility of Texas	Lewis, Michael	Baylor College of Medicine	\$3,999,996
RP220544	ECI	1.8	CPRIT Early Clinical Investigator Award-Christopher Alvarez-Breckenridge	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,500,000
RP220606	HIHR	1.9	Developing a Novel Optogenetic Recombinase System to Study and Target Metastatic Cancer	Maddipati, Ravikanth	The University of Texas Southwestern Medical Center	\$250,000
RP220662	CFSA	1.9	UTHSCSA Cancer Genome Sequencing and Computation Core	Chen, Yidong	The University of Texas Health Science Center at San Antonio	\$3,998,688
RP220650	HIHR	1.9	Targeting Nitric Oxide Synthase (NOS) Pathway to Remodel Obesity-Induced	Chang, Jenny	The Methodist Hospital Research Institute	\$250,000

ID	RFA	Score	Application Title	PI	PI Organization	Budget
			Tumor Inflammation in Patients With TNBC			
RP220631	CFSA	1.9	West Texas Pharmacology Core	Kang, Min	Texas Tech University Health Sciences Center	\$3,369,480
RP220542	CTNA	1.9	Establish the Accelerating Clinical Oncology Research Network-Texas (ACORN-TX) to Enhance Clinical Trial Access in North and Central Texas	Beg, Muhammad	The University of Texas Southwestern Medical Center	\$3,000,000
RP220626	HIHR	2.0	A Glia-to-Neuron Conversion for Treating Oral Cancer Pain	Tao, Feng	Texas A&M University System Health Science Center	\$237,500
RP220558	HIHR	2.0	Novel Covalent Drugs for BCL6	Fast, Walter	The University of Texas at Austin	\$249,999
RP220614	HIHR	2.0	Understanding the Impact of Immunity on Premalignant Somatic Mosaicism and Cancer Prevention	Zhu, Hao	The University of Texas Southwestern Medical Center	\$237,501
RP220666	HIHR	2.0	Targeting Tumors and the Tumor Microenvironment with Banana Lectin-Expressing T Cells	McKenna, Katie	Baylor College of Medicine	\$250,000
RP220567	HIHR	2.0	Fasting-Induced Microbiome Changes and Radioprotection	Piwnicka-Worms, Helen	The University of Texas M. D. Anderson Cancer Center	\$249,999
RP220645	HIHR	2.0	Ultrasensitive Nanosensor-Based Detection of Tumor Immunogenic Peptides to Enable Personalized Cancer Immunotherapy	Alexandrakis, Georgios	The University of Texas at Arlington	\$250,000
RP220581	ECI	2.1	Hyperspectral, Quantitative Intraoperative Fluorescence Image-Guided Brain Surgery	Urban, Randall	The University of Texas Medical Branch at Galveston	\$1,494,784
RP220599	CFSA	2.3	Texas Pediatric Cancer Testing (TPCT) Core	Houghton, Peter	The University of Texas Health Science Center at San Antonio	\$3,935,480
RP220653	HIHR	2.3	Novel Modulators of Genomic Instability in Human Cells	Vasquez, Karen	The University of Texas at Austin	\$249,932
RP220587	CFSA	2.3	Advanced Protein Therapeutics Core	Maynard, Jennifer	The University of Texas at Austin	\$3,995,180

ID	RFA	Score	Application Title	PI	PI Organization	Budget
RP220592	HIHR	2.4	Restoration of Phagocytosis Function of Glioma-Associated Microglia/Macrophage by Activating QKI-PPARb-RXRa	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$250,000
RP220600	HIHR	2.4	In Vivo Akt Analysis via Chemical Genetics and Nanoparticle-Mediated Probe Delivery	Wang, Degeng	Texas Tech University	\$249,999
RP220610	HIHR	2.8	Identification of Enhancers of T-Cell Antitumor Activity in PDAC Using CRISPR Activation Screening	Maitra, Anirban	The University of Texas M. D. Anderson Cancer Center	\$250,000
RP220553	HIHR	2.9	Reversing Aging-Associated Resistance to Cancer Immunotherapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$249,976
RP220639	HIHR	2.9	Targeting NHE6 to Improve Clinical Efficacy of Daratumumab in Myeloma	Yang, Jing	The Methodist Hospital Research Institute	\$250,000

ECI – Early Clinical Investigator Award
CFSA – Core Facilities Support Award
HIHR – High Impact High Risk Research Award
CTNA – Clinical Trial Network Award

Dr. Le Beau noted that the SRC and the PIC recommended two recruitment applications, totaling \$4,000,000. However, the applicant institutions withdrew the applications after the PIC meeting and prior to the Oversight Committee Meeting.

There were no questions for Dr. Le Beau.

Approval Process – Academic Research Awards

Presiding Officer Dr. Rice noted for the record that no Oversight Committee member had reported a conflict with any award recommendation presented today.

MOTION:

On a motion made by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee members voted unanimously to approve the PIC’s recommendations for the High-Impact/High Risk Awards, Core Facility Support Awards, Clinical Trial Network Awards and Early Clinical Investigator Awards.

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Patel, the Oversight Committee members voted to approve the delegation of contract negotiation authority to CPRIT’s CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

Chief Product Development Officer Report – Agenda Item 7

Presiding Officer Dr. Rice recognized Chief Product Development Officer Dr. Ken Smith to present the Product Development Research update and the recommended product development award. Dr. Smith presented the proposed product development award recommended by the PIC for ImmuneSensor, totaling \$16,154,562. Dr. Smith noted that this proposed award was one of the applications submitted for Cycle 22.2. Due to limited funding available for product development awards in FY 2022, the PDRC did not act to make a final recommendation until early September.

There were no questions for Dr. Smith.

Approval Process – Product Development Research Awards

Presiding Officer Dr. Rice noted for the record that no Oversight Committee member had reported a conflict with the award recommendation presented today for ImmuneSensor.

MOTION:

On a motion made by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee members voted unanimously to approve the PIC's recommendation for the product development research award to ImmuneSensor as presented by Dr. Smith.

MOTION:

On a motion made by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee members voted to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Patel, the Oversight Committee unanimously voted to authorize CPRIT to disburse grant funds via advance upon execution of the award contracts and the successful completion of tranches to ImmuneSensor.

Scientific Research and Prevention Program Committee Appointments – Agenda Item 8

Presiding Officer Rice recognized Mr. Roberts to present his 23 appointments to the peer review panels.

MOTION:

On a motion by Mr. Margo and seconded by Dr. Patel, the Oversight Committee unanimously voted to approve the CEO's 23 appointments to the Scientific Research and Prevention Program Committee.

Future Meeting Dates and Agenda Items – Agenda Item 12

Presiding Officer Dr. Rice announced that the Oversight Committee would not take up standing agenda items 9, 10 and 11.

He reminded members that CPRIT will meet in person for its next regularly quarterly meeting on November 16, 2022.

Adjournment – Agenda Item 25

MOTION:

There being no further business, the Oversight Committee unanimously voted to approve Presiding Officer Dr. Rice’s motion to adjourn, which Mr. Montgomery seconded.

Meeting adjourned at 9:28 a.m.



Signature *Cynthia Barberis Payne* Date *11/16/22*

LUDWIG CANCER RESEARCH

San Diego

ludwigcancerresearch.org

Cindy Barbario Payne
8/17/2022

Rank	App. ID	Mechanism	Candidate	Organization	Budget	Overall Scores
1	RR220084	RFTFM	Linde Miles	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
2	RR220087	RRS	Hans Renata	Rice University	\$4,000,000	1.0
3	RR220068	RFTFM	Elizabeth Wasmuth	The University of Texas Health Science Center at San Antonio	\$2,000,000	1.0
4	RR220069	RFTFM	William Hudson	Baylor College of Medicine	\$2,000,000	1.0
5	RR220075	RFTFM	Nicholas Riley	The University of Texas at Austin	\$2,000,000	1.0
6	RR220033	REI	Pavan Reddy	Baylor College of Medicine	\$6,000,000	1.0
7	RR220062	RFTFM	Aria Vaishnavi	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
8	RR220065	RFTFM	Mingjie Dai	Rice University	\$2,000,000	1.4
9	RR220072	RRS	Christine Lovly	The University of Texas M. D. Anderson Cancer Center	\$4,000,000	1.4
10	RR220063	RRS	Ku-Lung Hsu	The University of Texas at Austin	\$4,000,000	1.7
11	RR220051	REI	Michael Taylor	Baylor College of Medicine	\$6,000,000	1.8
12	RR220081	RFTFM	Jonathan Clinger	Baylor University	\$1,998,029	2.0
13	RR220086	RFTFM	Jason Schenkel	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.0
14	RR220088	RRS	Abdel Kareem Azab	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
15	RR220067	REI	Zhiguo Zhang	The University of Texas M. D. Anderson Cancer Center	\$6,000,000	2.0
16	RR220070	RRS	Marios Giannakis	The University of Texas Southwestern Medical Center	\$4,000,000	2.0
17	RR220055	RFTFM	Samantha Yruegas	Rice University	\$2,000,000	2.0
18	RR220066	RFTFM	Deepshika Ramanan	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.2
19	RR220035	RFTFM	Qian Zhu	Baylor College of Medicine	\$2,000,000	2.5


REI = Recruitment of Established Investigator

RRS = Recruitment of Rising Stars

RFTFM = Recruitment of First-Time, Tenure Track Faculty Members

LUDWIG CANCER RESEARCH

San Diego


Cindy Barbaro Payne
8/17/2022

ludwigcancerresearch.org

Rank	App. ID	Mechanism	Candidate	Organization	Budget	Overall Scores
1	RR220094	RFTFM	Steven Boeynaems, Ph.D.	Baylor College of Medicine	\$2,000,000	1.0
2	RR220101	RFTFM	Siqi Liu, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	1.0

RFTFM = Recruitment of First-Time, Tenure Track Faculty Members